Oligonucleotide Toxicity (OligoTox) Open Data Challenge
Pays cash prizes for public datasets that help predict oligonucleotide drug toxicity in human cells.
OligoTox is a two-phase prize competition seeking publicly accessible, high-quality datasets built from in vitro human-based systems -- such as organs-on-a-chip, 3D organoids or cell cultures -- that can train AI models to predict oligonucleotide toxicity from sequence and chemical modification, reducing reliance on animal studies. The toxicities NCATS is most interested in span organ and system e…
Looks for high-quality, publicly accessible datasets built from in vitro human-based systems, such as organs-on-a-chip or human cell cultures, that measure oligonucleotide toxicities like liver damage, kidney toxicity, immune reactions or blood clotting effects. Datasets should link an oligo's sequence and chemical modifications to these toxicity outcomes so they can train predictive AI models.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see how they score you
Sign up free to see the timeline
Sign up free to see where teams trip up
Guides for this application
All guides →NIH Biosketch Guide: Format, SciENcv Steps, and Examples
Learn what an NIH biosketch is, how the format works, what to prepare for SciENcv, and how startup teams should avoid common biosketch mistakes.
Write proposalHow to Write a Specific Aims Page
Learn how to write a specific aims page for NIH, SBIR-adjacent, and translational R&D grants, with structure, reviewer logic, examples, and common mistakes.
Where to applyGrants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
Write proposalHow to Write a Grant Proposal Reviewers Can Score
Learn how to write a grant proposal around reviewer criteria, evidence, work packages, budget logic, and commercialization for deeptech and R&D funding.
More from NCATS
All grants from this funder →NCATS Clinical Trial Readiness for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies generating natural history data, biomarkers, and outcome measures needed to design clinical trials for rare diseases.
NCATS Preclinical Proof of Concept Studies for Rare Diseases
🇺🇸NCATS · United States
Funds U.S. researchers and companies conducting preclinical efficacy studies to advance therapeutic candidates for rare diseases toward IND applications.
NCATS STTR Phase I
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to conduct feasibility studies on translational science innovations toward commercialization.
NCATS STTR Phase II
🇺🇸NCATS · United States
Funds U.S. small businesses and their nonprofit research partners to continue and expand translational R&D begun in STTR Phase I toward a commercial product.
ASPIRE Reduction-to-Practice (Seed)
🇺🇸NCATS · United States
Supports translational chemistry and automation platform development through university-linked partnerships.
NCATS SBIR Phase I
🇺🇸NCATS · United States
Supports small businesses testing translational science tools and technologies through early feasibility and commercialization groundwork.
Similar grants
Browse the directory →NOURISH: Autoimmunity Digital Health Challenge
🇺🇸OADR-ORWH · United States
Awards up to $650,000 across three phases for digital tools tracking autoimmune nutrition.
NIA Start-Up Challenge
🇺🇸NIA · United States
Funds US entrepreneurs and small businesses developing healthy-aging technologies through NIA's Start-Up Challenge cash prizes and accelerator.
Complement-ARIE Challenge
🇺🇸NIH Common Fund · United States
Pays up to $50,000 each to 20 teams building human-based alternatives to animal testing.
Childhood, Adolescent and Young Adult (AYA) Cancer Data Innovation Challenge — Track 1
🇺🇸NCI · United States
Pays entities up to $566,665 across three milestones to add shovel-ready cancer data or tools to NCI's CCDI ecosystem.
MIT Solve Global Challenges
🇺🇸MIT · United States
Supports teams tackling global challenges by selecting and backing scalable ideas through MIT Solve challenge pathways.
TRDNT Challenge Phase II: Prototype Development and Use Case Demonstration
🇺🇸NIH · United States
Pays up to $120,000 per Interim Milestone winner and up to $320,000 per Final Submission winner to US-based researchers, startups and institutions that build a working prototype technology able to target endogenous RNA in human disease.